Blockchain Registration Transaction Record

Quantum BioPharma Taps Thermo Fisher for Phase 2 Lucid-MS Trial

Quantum BioPharma partners with Thermo Fisher's clinical research business to launch a Phase 2 trial of Lucid-MS, a novel neuroprotective MS treatment.

This news matters because it signals a potential shift in how multiple sclerosis is treated. Current therapies primarily suppress the immune system, which can leave patients vulnerable to infections and may not address the underlying nerve damage. If Lucid-MS succeeds in Phase 2 trials, it could become the first therapy to directly protect myelin, offering new hope for halting or reversing disability. The involvement of Thermo Fisher’s clinical research business adds significant credibility and operational expertise, increasing the likelihood of a well-executed trial. For investors, this de-risks the development path and highlights Quantum BioPharma’s innovative pipeline. For patients, it represents a novel mechanism that could one day transform MS care from immune modulation to true neuroprotection, potentially improving quality of life and long-term outcomes.